Priming of human resting NK cells by autologous M1 macrophages via the engagement of IL-1b, IFN-β, and IL-15 pathways

Journal of Immunology

Volumn 195, Issue 6, 2015, Pages 2818-2828

  Mattiola, Irene ^a,b   Pesant, Matthieu ^a   Tentorio, Paolo F ^a   Molgora, Martina ^a,b   Marcenaro, Emanuela ^c   Lugli, Enrico ^a   Locati, Massimo ^a,b   Mavilio, Domenico ^a,b  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; CD48 ANTIGEN; CD69 ANTIGEN; CYTOCHROME P450 2B4; GAMMA INTERFERON; INTERLEUKIN 12P70; INTERLEUKIN 15; INTERLEUKIN 15 RECEPTOR ALPHA; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 23; INTERLEUKIN 23P19; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MACROPHAGE DERIVED CHEMOKINE; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 2; NATURAL KILLER CELL RECEPTOR NKG2D; CD244 PROTEIN, HUMAN; IL15 PROTEIN, HUMAN; IL1B PROTEIN, HUMAN; IL23A PROTEIN, HUMAN; IMMUNOGLOBULIN RECEPTOR; KLRK1 PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY K; NCR2 PROTEIN, HUMAN;

ANTIGEN EXPRESSION; ARTICLE; CELL CONTACT; CELL INTERACTION; CELL MEDIATED CYTOTOXICITY; CELLULAR IMMUNITY; CONTROLLED STUDY; CROSS PRESENTATION; CYTOKINE PRODUCTION; CYTOKINE RELEASE; EMBRYO; HUMAN; HUMAN CELL; IMMUNOREGULATION; INNATE IMMUNITY; INTRACELLULAR SIGNALING; MACROPHAGE; MOLECULAR DYNAMICS; NATURAL KILLER CELL; PHENOTYPE; PRIORITY JOURNAL; UPREGULATION; BIOSYNTHESIS; CELL COMMUNICATION; CELL PROLIFERATION; HEK293 CELL LINE; IMMUNOLOGY; JURKAT CELL LINE; LYMPHOCYTE ACTIVATION; METABOLISM; TUMOR CELL LINE;

ANTIGENS, CD; CELL COMMUNICATION; CELL LINE, TUMOR; CELL PROLIFERATION; HEK293 CELLS; HUMANS; IMMUNITY, INNATE; INTERFERON-BETA; INTERFERON-GAMMA; INTERLEUKIN-15; INTERLEUKIN-1BETA; INTERLEUKIN-23 SUBUNIT P19; JURKAT CELLS; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MACROPHAGES; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 2; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; RECEPTORS, IMMUNOLOGIC;

EID: 84941790490     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1500325     Document Type: Article

References (67)

1. Vivier, E., E. Tomasello, M. Baratin, T. Walzer, and S. Ugolini. 2008. Functions of natural killer cells. Nat. Immunol. 9: 503-510.
2. Moretta, A. 2002. Natural killer cells and dendritic cells: rendezvous in abused tissues. Nat. Rev. Immunol. 2: 957-964.
3. Moretta, A., C. Bottino, M. Vitale, D. Pende, R. Biassoni, M. C. Mingari, and L. Moretta. 1996. Receptors for HLA class-I molecules in human natural killer cells. Annu. Rev. Immunol. 14: 619-648.
4. Lanier, L. L. 2005. NK cell recognition. Annu. Rev. Immunol. 23: 225-274.
5. Brunetta, E., K. L. Hudspeth, and D. Mavilio. 2010. Pathologic natural killer cell subset redistribution in HIV-1 infection: new insights in pathophysiology and clinical outcomes. J. Leukoc. Biol. 88: 1119-1130.
6. Mills, C. D., K. Kincaid, J. M. Alt, M. J. Heilman, and A. M. Hill. 2000. M-1/M-2 macrophages and the Th1/Th2 paradigm. J. Immunol. 164: 6166-6173.
7. Murray, P. J., J. E. Allen, S. K. Biswas, E. A. Fisher, D. W. Gilroy, S. Goerdt, S. Gordon, J. A. Hamilton, L. B. Ivashkiv, T. Lawrence, et al. 2014. Macrophage activation and polarization: nomenclature and experimental guidelines. [Published erratum appears in 2014 Immunity. 41: 339-340.] Immunity 41: 14-20.
8. Mosser, D. M., and J. P. Edwards. 2008. Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol. 8: 958-969.
9. Murray, P. J., and T. A. Wynn. 2011. Protective and pathogenic functions of macrophage subsets. Nat. Rev. Immunol. 11: 723-737.
10. Mantovani, A., A. Sica, S. Sozzani, P. Allavena, A. Vecchi, and M. Locati. 2004. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 25: 677-686.
11. Biswas, S. K., and A. Mantovani. 2010. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat. Immunol. 11: 889-896.
12. Steidl, C., T. Lee, S. P. Shah, P. Farinha, G. Han, T. Nayar, A. Delaney, S. J. Jones, J. Iqbal, D. D. Weisenburger, et al. 2010. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N. Engl. J. Med. 362: 875-885.
13. Mantovani, A., P. Allavena, A. Sica, and F. Balkwill. 2008. Cancer-related inflammation. Nature 454: 436-444.
14. Noy, R., and J. W. Pollard. 2014. Tumor-associated macrophages: from mechanisms to therapy. [Published erratum appears in 2014 Immunity. 41: 866.] Immunity 41: 49-61.
15. Bellora, F., R. Castriconi, A. Dondero, G. Reggiardo, L. Moretta, A. Mantovani, A. Moretta, and C. Bottino. 2010. The interaction of human natural killer cells with either unpolarized or polarized macrophages results in different functional outcomes. Proc. Natl. Acad. Sci. USA 107: 21659-21664.
16. Nedvetzki, S., S. Sowinski, R. A. Eagle, J. Harris, F. Vély, D. Pende, J. Trowsdale, E. Vivier, S. Gordon, and D. M. Davis. 2007. Reciprocal regulation of human natural killer cells and macrophages associated with distinct immune synapses. Blood 109: 3776-3785.
17. Michel, T., F. Hentges, and J. Zimmer. 2012. Consequences of the crosstalk between monocytes/macrophages and natural killer cells. Front. Immunol. 3: 403.
18. Costantini, C., F. Calzetti, O. Perbellini, A. Micheletti, C. Scarponi, S. Lonardi, M. Pelletier, K. Schakel, G. Pizzolo, F. Facchetti, et al. 2011. Human neutrophils interact with both 6-sulfo LacNAc+ DC and NK cells to amplify NK-derived IFNgamma: role of CD18, ICAM-1, and ICAM-3. Blood 117: 1677-1686.
19. Lapaque, N., T. Walzer, S. Méresse, E. Vivier, and J. Trowsdale. 2009. Interactions between human NK cells and macrophages in response to Salmonella infection. J. Immunol. 182: 4339-4348.
20. Romo, N., G. Magri, A. Muntasell, G. Heredia, D. Baía, A. Angulo, M. Guma, and M. López-Botet. 2011. Natural killer cell-mediated response to human cytomegalovirus-infected macrophages is modulated by their functional polarization. J. Leukoc. Biol. 90: 717-726.
21. Cooper, M. A., T. A. Fehniger, and M. A. Caligiuri. 2001. The biology of human natural killer-cell subsets. Trends Immunol. 22: 633-640.
22. Fehniger, T. A., and M. A. Caligiuri. 2001. Interleukin 15: biology and relevance to human disease. Blood 97: 14-32.
23. Jakobisiak, M., J. Golab, and W. Lasek. 2011. Interleukin 15 as a promising candidate for tumor immunotherapy. Cytokine Growth Factor Rev. 22: 99-108.
24. Steel, J. C., T. A. Waldmann, and J. C. Morris. 2012. Interleukin-15 biology and its therapeutic implications in cancer. Trends Pharmacol. Sci. 33: 35-41.
25. Bergamaschi, C., J. Bear, M. Rosati, R. K. Beach, C. Alicea, R. Sowder, E. Chertova, S. A. Rosenberg, B. K. Felber, and G. N. Pavlakis. 2012. Circulating IL-15 exists as heterodimeric complex with soluble IL-15Ra in human and mouse serum. Blood 120: e1-e8.
26. Zanoni, I., R. Spreafico, C. Bodio, M. Di Gioia, C. Cigni, A. Broggi, T. Gorletta, M. Caccia, G. Chirico, L. Sironi, et al. 2013. IL-15 cis presentation is required for optimal NK cell activation in lipopolysaccharide-mediated inflammatory conditions. Cell Reports 4: 1235-1249.
27. Cella, M., K. Otero, and M. Colonna. 2010. Expansion of human NK-22 cells with IL-7, IL-2, and IL-1beta reveals intrinsic functional plasticity. Proc. Natl. Acad. Sci. USA 107: 10961-10966.
28. Hughes, T., B. Becknell, A. G. Freud, S. McClory, E. Briercheck, J. Yu, C. Mao, C. Giovenzana, G. Nuovo, L. Wei, et al. 2010. Interleukin-1beta selectively expands and sustains interleukin-22+ immature human natural killer cells in secondary lymphoid tissue. Immunity 32: 803-814.
29. Glatzer, T., M. Killig, J. Meisig, I. Ommert, M. Luetke-Eversloh, M. Babic, D. Paclik, N. Blüthgen, R. Seidl, C. Seifarth, et al. 2013. RORgt innate lymphoid cells acquire a proinflammatory program upon engagement of the activating receptor NKp44. Immunity 38: 1223-1235.
30. Spits, H., D. Artis, M. Colonna, A. Diefenbach, J. P. Di Santo, G. Eberl, S. Koyasu, R. M. Locksley, A. N. McKenzie, R. E. Mebius, et al. 2013. Innate lymphoid cells-a proposal for uniform nomenclature. Nat. Rev. Immunol. 13: 145-149.
31. Cooper, M. A., T. A. Fehniger, A. Ponnappan, V. Mehta, M. D. Wewers, and M. A. Caligiuri. 2001. Interleukin-1beta costimulates interferon-gamma production by human natural killer cells. Eur. J. Immunol. 31: 792-801.
32. van de Wetering, D., R. A. de Paus, J. T. van Dissel, and E. van de Vosse. 2009. Salmonella induced IL-23 and IL-1beta allow for IL-12 production by monocytes and Mphi1 through induction of IFN-gamma in CD56 NK/NK-like T cells. PLoS One 4: e8396.
33. Gupta, N., J. Arthos, P. Khazanie, T. D. Steenbeke, N. M. Censoplano, E. A. Chung, C. C. Cruz, M. A. Chaikin, M. Daucher, S. Kottilil, et al. 2005. Targeted lysis of HIV-infected cells by natural killer cells armed and triggered by a recombinant immunoglobulin fusion protein: implications for immunotherapy. Virology 332: 491-497.
34. Solinas, G., S. Schiarea, M. Liguori, M. Fabbri, S. Pesce, L. Zammataro, F. Pasqualini, M. Nebuloni, C. Chiabrando, A. Mantovani, and P. Allavena. 2010. Tumor-conditioned macrophages secrete migration-stimulating factor: a new marker for M2-polarization, influencing tumor cell motility. J. Immunol. 185: 642-652.
35. Brunetta, E., M. Fogli, S. Varchetta, L. Bozzo, K. L. Hudspeth, E. Marcenaro, A. Moretta, and D. Mavilio. 2009. The decreased expression of Siglec-7 represents an early marker of dysfunctional natural killer-cell subsets associated with high levels of HIV-1 viremia. Blood 114: 3822-3830.
36. Alter, G., J.M.Malenfant, and M. Altfed. 2004. CD107a as a functional marker for the identification of natural killer cell activity. J. Immunol. Methods 294: 15-22.
37. Mavilio, D., J. Benjamin, M. Daucher, G. Lombardo, S. Kottilil, M. A. Planta, E. Marcenaro, C. Bottino, L. Moretta, A. Moretta, and A. S. Fauci. 2003. Natural killer cells in HIV-1 infection: dichotomous effects of viremia on inhibitory and activating receptors and their functional correlates. Proc. Natl. Acad. Sci. USA 100: 15011-15016.
38. Varchetta, S., B. Oliviero, D. Mavilio, and M. U. Mondelli. 2013. Different combinations of cytokines and activating receptor stimuli are required for human natural killer cell functional diversity. Cytokine 62: 58-63.
39. Martinez, F. O., S. Gordon, M. Locati, and A. Mantovani. 2006. Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J. Immunol. 177: 7303-7311.
40. Biswas, S. K., P. Allavena, and A. Mantovani. 2013. Tumor-associated macrophages: functional diversity, clinical significance, and open questions. Semin. Immunopathol. 35: 585-600.
41. Bernink, J. H., C. P. Peters, M. Munneke, A. A. te Velde, S. L. Meijer, K. Weijer, H. S. Hreggvidsdottir, S. E. Heinsbroek, N. Legrand, C. J. Buskens, et al. 2013. Human type 1 innate lymphoid cells accumulate in inflamed mucosal tissues. Nat. Immunol. 14: 221-229.
42. Garlanda, C., F. Riva, E. Bonavita, and A. Mantovani. 2013. Negative regulatory receptors of the IL-1 family. Semin. Immunol. 25: 408-415.
43. Scotton, C. J., F. O. Martinez, M. J. Smelt, M. Sironi, M. Locati, A. Mantovani, and S. Sozzani. 2005. Transcriptional profiling reveals complex regulation of the monocyte IL-1 beta system by IL-13. J. Immunol. 174: 834-845.
44. Wehner, R., A. Bitterlich, N. Meyer, A. Kloss, K. Schakel, M. Bachmann, and M. Schmitz. 2013. Impact of chemotherapeutic agents on the immunostimulatory properties of human 6-sulfo LacNAc+ (slan) dendritic cells. Int. J. Cancer 132: 1351-1359.
45. Zhou, Z., C. Zhang, J. Zhang, and Z. Tian. 2012. Macrophages help NK cells to attack tumor cells by stimulatory NKG2D ligand but protect themselves from NK killing by inhibitory ligand Qa-1. PLoS One 7: e36928.
46. Zhang, C., J. Zhang, J. Niu, Z. Zhou, J. Zhang, and Z. Tian. 2008. Interleukin-12 improves cytotoxicity of natural killer cells via upregulated expression of NKG2D. Hum. Immunol. 69: 490-500.
47. Zhu, S., P. V. Phatarpekar, C. J. Denman, V. V. Senyukov, S. S. Somanchi, H. T. Nguyen-Jackson, E. M. Mace, A. F. Freeman, S. S. Watowich, J. S. Orange, et al. 2014. Transcription of the activating receptor NKG2D in natural killer cells is regulated by STAT3 tyrosine phosphorylation. Blood 124: 403-411.
48. Bae, D. S., Y. K. Hwang, and J. K. Lee. 2012. Importance of NKG2D-NKG2D ligands interaction for cytolytic activity of natural killer cell. Cell. Immunol. 276: 122-127.
49. Baychelier, F., A. Sennepin, M. Ermonval, K. Dorgham, P. Debré, and V. Vieillard. 2013. Identification of a cellular ligand for the natural cytotoxicity receptor NKp44. Blood 122: 2935-2942.
50. Byrd, A., S. C. Hoffmann, M. Jarahian, F. Momburg, and C. Watzl. 2007. Expression analysis of the ligands for the Natural Killer cell receptors NKp30 and NKp44. PLoS One 2: e1339.
51. Horng, T., J. S. Bezbradica, and R. Medzhitov. 2007. NKG2D signaling is coupled to the interleukin 15 receptor signaling pathway. Nat. Immunol. 8: 1345-1352.
52. Tamassia, N., V. Le Moigne, F. Calzetti, M. Donini, S. Gasperini, T. Ear, A. Cloutier, F. O. Martinez, M. Fabbri, M. Locati, et al. 2007. The MyD88-independent pathway is not mobilized in human neutrophils stimulated via TLR4. J. Immunol. 178: 7344-7356.
53. Yang, H. T., Y. Wang, X. Zhao, E. Demissie, S. Papoutsopoulou, A. Mambole, A. O'Garra, M. F. Tomczak, S. E. Erdman, J. G. Fox, et al. 2011. NF-kB1 inhibits TLR-induced IFN-b production in macrophages through TPL-2-dependent ERK activation. J. Immunol. 186: 1989-1996.
54. Hudspeth, K., E. Pontarini, P. Tentorio, M. Cimino, M. Donadon, G. Torzilli, E. Lugli, S. Della Bella, M. E. Gershwin, and D. Mavilio. 2013. The role of natural killer cells in autoimmune liver disease: a comprehensive review. J. Autoimmun. 46: 55-65.
55. Zhang, C., J. Zhang, R. Sun, J. Feng, H. Wei, and Z. Tian. 2005. Opposing effect of IFNgamma and IFNalpha on expression of NKG2 receptors: negative regulation of IFNgamma on NK cells. Int. Immunopharmacol. 5: 1057-1067.
56. Goriely, S., M. F. Neurath, and M. Goldman. 2008. How microorganisms tip the balance between interleukin-12 family members. Nat. Rev. Immunol. 8: 81-86.
57. Hayakawa, Y., N. D. Huntington, S. L. Nutt, and M. J. Smyth. 2006. Functional subsets of mouse natural killer cells. Immunol. Rev. 214: 47-55.
58. Moretta, A., C. Bottino, M. Vitale, D. Pende, C. Cantoni, M. C. Mingari, R. Biassoni, and L. Moretta. 2001. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu. Rev. Immunol. 19: 197-223.
59. Mortier, E., R. Advincula, L. Kim, S. Chmura, J. Barrera, B. Reizis, B. A. Malynn, and A. Ma. 2009. Macrophage- and dendritic-cell-derived interleukin-15 receptor alpha supports homeostasis of distinct CD8+ T cell subsets. Immunity 31: 811-822.
60. Veillette, A. 2006. Immune regulation by SLAM family receptors and SAPrelated adaptors. Nat. Rev. Immunol. 6: 56-66.
61. Herbein, G., and A. Varin. 2010. The macrophage in HIV-1 infection: from activation to deactivation? Retrovirology 7: 33.
62. Varchetta, S., P. Lusso, K. Hudspeth, J. Mikulak, D. Mele, S. Paolucci, R. Cimbro, M. Malnati, A. Riva, R. Maserati, et al. 2013. Sialic acid-binding Iglike lectin-7 interacts with HIV-1 gp120 and facilitates infection of CD4pos T cells and macrophages. Retrovirology 10: 154.
63. Hanahan, D., and L. M. Coussens. 2012. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 21: 309-322.
64. Qian, B. Z., J. Li, H. Zhang, T. Kitamura, J. Zhang, L. R. Campion, E. A. Kaiser, L. A. Snyder, and J. W. Pollard. 2011. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 475: 222-225.
65. Ries, C. H.,M.A. Cannarile, S. Hoves, J.Benz,K. Wartha, V. Runza, F. Rey-Giraud, L. P. Pradel, F. Feuerhake, I. Klaman, et al. 2014. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell 25: 846-859.
66. Beatty, G. L., E. G. Chiorean, M. P. Fishman, B. Saboury, U. R. Teitelbaum, W. Sun, R. D. Huhn, W. Song, D. Li, L. L. Sharp, et al. 2011. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 331: 1612-1616.
67. Hagemann, T., T. Lawrence, I. McNeish, K. A. Charles, H. Kulbe, R. G. Thompson, S. C. Robinson, and F. R. Balkwill. 2008. "Re-educating" tumor-associated macrophages by targeting NF-kappaB. J. Exp. Med. 205: 1261-1268.